NCT04278326 2025-04-20
ORGANOIDES
Centre Hospitalier Régional d'Orléans
Phase NA Terminated
Clinical Trials
13 trialsNCT02827838 2025-03-17
Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer
Wake Forest University Health Sciences
Phase EARLY_PHASE1 Terminated
NCT03610581 2025-02-04
Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix
Janssen Vaccines & Prevention B.V.
Phase 1/2 Terminated
NCT03912831 2023-12-26
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
Gilead Sciences
Phase 1 Terminated
NCT03258008 2022-12-16
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01891695 2022-10-12
OPSCC N0 Nodal Control With Reduced IMRT
University of Virginia
Phase NA Terminated
NCT02354144 2021-06-15
LIMIT-HPV
McGill University
Phase 2/3 Terminated
NCT03937791 2021-04-13
Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03677960 2019-07-24
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
Antiva Biosciences
Phase 1 Terminated
NCT02706691 2019-04-16
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
University of Chicago
Phase 2 Terminated
NCT00312286 2016-09-23
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
Takeda
Phase 2 Terminated
NCT00117884 2016-08-19
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
Takeda
Phase 2 Terminated
NCT01082861 2010-03-19
TANGO
National Institute for Public Health and the Environment (RIVM)
Phase 4 Terminated